Global Dipeptide Peptidase 4 (DPP-4) Inhibitors market is expected to grow from US$ 9642 million in 2025 to US$ 11110 million in 2031; it is expected to grow at a CAGR of 2.4% from 2025 to 2031.

Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Market Size and Outlook 2025-31

The global Dipeptide Peptidase 4 (DPP-4) Inhibitors market size is predicted to grow from US$ 9642 million in 2025 to US$ 11110 million in 2031; it is expected to grow at a CAGR of 2.4% from 2025 to 2031. The impact of the latest U.S. tariff measures and the corresponding policy responses from countries worldwide on market competitiveness, regional economic performance, and supply chain configurations will be comprehensively evaluated in this report. Dipeptide Peptidase 4 (DPP-4) Inhibitors are a class of oral diabetes drugs that work by blocking the action of DPP-4, an enzyme which destroys a group of gastrointestinal hormones called incretins. Incretins help stimulate the production of insulin when it is needed (e.g. after eating) and reduce the production of glucagon by the liver when it is not needed (e.g. during digestion). They also slow down digestion and decrease appetite. So by protecting incretins from damage, DPP-4 inhibitors help regulate blood glucose levels. Januvia (Sitagliptin), Galvus (Vildagliptin), Onglyza (Saxagliptin), Tradjenta (Linagliptin) are the major DPP-4 drugs in the market. Infinity Market Research newest research report, the Dipeptide Peptidase 4 (DPP-4) Inhibitors Industry Forecast looks at past sales and reviews total world Dipeptide Peptidase 4 (DPP-4) Inhibitors sales in 2024, providing a comprehensive analysis by region and market sector of projected Dipeptide Peptidase 4 (DPP-4) Inhibitors sales for 2025 through 2031. With Dipeptide Peptidase 4 (DPP-4) Inhibitors sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Dipeptide Peptidase 4 (DPP-4) Inhibitors industry. This Insight Report provides a comprehensive analysis of the global Dipeptide Peptidase 4 (DPP-4) Inhibitors landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Dipeptide Peptidase 4 (DPP-4) Inhibitors portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms unique position in an accelerating global Dipeptide Peptidase 4 (DPP-4) Inhibitors market. This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Dipeptide Peptidase 4 (DPP-4) Inhibitors and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Dipeptide Peptidase 4 (DPP-4) Inhibitors. This report presents a comprehensive overview, market shares, and growth opportunities of Dipeptide Peptidase 4 (DPP-4) Inhibitors market by product type, application, key manufacturers and key regions and countries. Segmentation by Type: &nbsp;&nbsp;&nbsp; Sitagliptin &nbsp;&nbsp;&nbsp; Saxagliptin &nbsp;&nbsp;&nbsp; Linagliptin &nbsp;&nbsp;&nbsp; Alogliptin &nbsp;&nbsp;&nbsp; Vildagliptin Segmentation by Application: &nbsp;&nbsp;&nbsp; Hospitals &nbsp;&nbsp;&nbsp; Clinics This report also splits the market by region: &nbsp;&nbsp;&nbsp; Americas &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; United States &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Canada &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Mexico &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Brazil &nbsp;&nbsp;&nbsp; APAC &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; China &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Japan &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Korea &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Southeast Asia &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; India &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Australia &nbsp;&nbsp;&nbsp; Europe &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Germany &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; France &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; UK &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Italy &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Russia &nbsp;&nbsp;&nbsp; Middle East & Africa &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Egypt &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; South Africa &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Israel &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Turkey &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; GCC Countries The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the companys coverage, product portfolio, its market penetration. &nbsp;&nbsp;&nbsp; Merck &nbsp;&nbsp;&nbsp; Eli Lilly &nbsp;&nbsp;&nbsp; AstraZenica &nbsp;&nbsp;&nbsp; Boehringer Ingelheim &nbsp;&nbsp;&nbsp; Takeda Pharmaceutical Company &nbsp;&nbsp;&nbsp; BMS Key Questions Addressed in this Report What is the 10-year outlook for the global Dipeptide Peptidase 4 (DPP-4) Inhibitors market? What factors are driving Dipeptide Peptidase 4 (DPP-4) Inhibitors market growth, globally and by region? Which technologies are poised for the fastest growth by market and region? How do Dipeptide Peptidase 4 (DPP-4) Inhibitors market opportunities vary by end market size? How does Dipeptide Peptidase 4 (DPP-4) Inhibitors break out by Type, by Application?

1 Scope of the Report &nbsp;1.1 Market Introduction &nbsp;1.2 Years Considered &nbsp;1.3 Research Objectives &nbsp;1.4 Market Research Methodology &nbsp;1.5 Research Process and Data Source &nbsp;1.6 Economic Indicators &nbsp;1.7 Currency Considered &nbsp;1.8 Market Estimation Caveats 2 Executive Summary &nbsp;2.1 World Market Overview &nbsp;2.1.1 Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Annual Sales 2020-2031 &nbsp;2.1.2 World Current & Future Analysis for Dipeptide Peptidase 4 (DPP-4) Inhibitors by Geographic Region, 2020, 2024 & 2031 &nbsp;2.1.3 World Current & Future Analysis for Dipeptide Peptidase 4 (DPP-4) Inhibitors by Country/Region, 2020, 2024 & 2031 &nbsp;2.2 Dipeptide Peptidase 4 (DPP-4) Inhibitors Segment by Type &nbsp;2.2.1 Sitagliptin &nbsp;2.2.2 Saxagliptin &nbsp;2.2.3 Linagliptin &nbsp;2.2.4 Alogliptin &nbsp;2.2.5 Vildagliptin &nbsp;2.3 Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales by Type &nbsp;2.3.1 Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Market Share by Type (2020-2025) &nbsp;2.3.2 Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Revenue and Market Share by Type (2020-2025) &nbsp;2.3.3 Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Sale Price by Type (2020-2025) &nbsp;2.4 Dipeptide Peptidase 4 (DPP-4) Inhibitors Segment by Application &nbsp;2.4.1 Hospitals &nbsp;2.4.2 Clinics &nbsp;2.5 Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales by Application &nbsp;2.5.1 Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Sale Market Share by Application (2020-2025) &nbsp;2.5.2 Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Revenue and Market Share by Application (2020-2025) &nbsp;2.5.3 Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Sale Price by Application (2020-2025) 3 Global by Company &nbsp;3.1 Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Breakdown Data by Company &nbsp;3.1.1 Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Annual Sales by Company (2020-2025) &nbsp;3.1.2 Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Market Share by Company (2020-2025) &nbsp;3.2 Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Annual Revenue by Company (2020-2025) &nbsp;3.2.1 Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Revenue by Company (2020-2025) &nbsp;3.2.2 Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Revenue Market Share by Company (2020-2025) &nbsp;3.3 Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Sale Price by Company &nbsp;3.4 Key Manufacturers Dipeptide Peptidase 4 (DPP-4) Inhibitors Producing Area Distribution, Sales Area, Product Type &nbsp;3.4.1 Key Manufacturers Dipeptide Peptidase 4 (DPP-4) Inhibitors Product Location Distribution &nbsp;3.4.2 Players Dipeptide Peptidase 4 (DPP-4) Inhibitors Products Offered &nbsp;3.5 Market Concentration Rate Analysis &nbsp;3.5.1 Competition Landscape Analysis &nbsp;3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025) &nbsp;3.6 New Products and Potential Entrants &nbsp;3.7 Market M&A Activity & Strategy 4 World Historic Review for Dipeptide Peptidase 4 (DPP-4) Inhibitors by Geographic Region &nbsp;4.1 World Historic Dipeptide Peptidase 4 (DPP-4) Inhibitors Market Size by Geographic Region (2020-2025) &nbsp;4.1.1 Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Annual Sales by Geographic Region (2020-2025) &nbsp;4.1.2 Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Annual Revenue by Geographic Region (2020-2025) &nbsp;4.2 World Historic Dipeptide Peptidase 4 (DPP-4) Inhibitors Market Size by Country/Region (2020-2025) &nbsp;4.2.1 Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Annual Sales by Country/Region (2020-2025) &nbsp;4.2.2 Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Annual Revenue by Country/Region (2020-2025) &nbsp;4.3 Americas Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Growth &nbsp;4.4 APAC Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Growth &nbsp;4.5 Europe Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Growth &nbsp;4.6 Middle East & Africa Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Growth 5 Americas &nbsp;5.1 Americas Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales by Country &nbsp;5.1.1 Americas Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales by Country (2020-2025) &nbsp;5.1.2 Americas Dipeptide Peptidase 4 (DPP-4) Inhibitors Revenue by Country (2020-2025) &nbsp;5.2 Americas Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales by Type (2020-2025) &nbsp;5.3 Americas Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales by Application (2020-2025) &nbsp;5.4 United States &nbsp;5.5 Canada &nbsp;5.6 Mexico &nbsp;5.7 Brazil 6 APAC &nbsp;6.1 APAC Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales by Region &nbsp;6.1.1 APAC Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales by Region (2020-2025) &nbsp;6.1.2 APAC Dipeptide Peptidase 4 (DPP-4) Inhibitors Revenue by Region (2020-2025) &nbsp;6.2 APAC Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales by Type (2020-2025) &nbsp;6.3 APAC Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales by Application (2020-2025) &nbsp;6.4 China &nbsp;6.5 Japan &nbsp;6.6 South Korea &nbsp;6.7 Southeast Asia &nbsp;6.8 India &nbsp;6.9 Australia &nbsp;6.10 China Taiwan 7 Europe &nbsp;7.1 Europe Dipeptide Peptidase 4 (DPP-4) Inhibitors by Country &nbsp;7.1.1 Europe Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales by Country (2020-2025) &nbsp;7.1.2 Europe Dipeptide Peptidase 4 (DPP-4) Inhibitors Revenue by Country (2020-2025) &nbsp;7.2 Europe Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales by Type (2020-2025) &nbsp;7.3 Europe Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales by Application (2020-2025) &nbsp;7.4 Germany &nbsp;7.5 France &nbsp;7.6 UK &nbsp;7.7 Italy &nbsp;7.8 Russia 8 Middle East & Africa &nbsp;8.1 Middle East & Africa Dipeptide Peptidase 4 (DPP-4) Inhibitors by Country &nbsp;8.1.1 Middle East & Africa Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales by Country (2020-2025) &nbsp;8.1.2 Middle East & Africa Dipeptide Peptidase 4 (DPP-4) Inhibitors Revenue by Country (2020-2025) &nbsp;8.2 Middle East & Africa Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales by Type (2020-2025) &nbsp;8.3 Middle East & Africa Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales by Application (2020-2025) &nbsp;8.4 Egypt &nbsp;8.5 South Africa &nbsp;8.6 Israel &nbsp;8.7 Turkey &nbsp;8.8 GCC Countries 9 Market Drivers, Challenges and Trends &nbsp;9.1 Market Drivers & Growth Opportunities &nbsp;9.2 Market Challenges & Risks &nbsp;9.3 Industry Trends 10 Manufacturing Cost Structure Analysis &nbsp;10.1 Raw Material and Suppliers &nbsp;10.2 Manufacturing Cost Structure Analysis of Dipeptide Peptidase 4 (DPP-4) Inhibitors &nbsp;10.3 Manufacturing Process Analysis of Dipeptide Peptidase 4 (DPP-4) Inhibitors &nbsp;10.4 Industry Chain Structure of Dipeptide Peptidase 4 (DPP-4) Inhibitors 11 Marketing, Distributors and Customer &nbsp;11.1 Sales Channel &nbsp;11.1.1 Direct Channels &nbsp;11.1.2 Indirect Channels &nbsp;11.2 Dipeptide Peptidase 4 (DPP-4) Inhibitors Distributors &nbsp;11.3 Dipeptide Peptidase 4 (DPP-4) Inhibitors Customer 12 World Forecast Review for Dipeptide Peptidase 4 (DPP-4) Inhibitors by Geographic Region &nbsp;12.1 Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Market Size Forecast by Region &nbsp;12.1.1 Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Forecast by Region (2026-2031) &nbsp;12.1.2 Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Annual Revenue Forecast by Region (2026-2031) &nbsp;12.2 Americas Forecast by Country (2026-2031) &nbsp;12.3 APAC Forecast by Region (2026-2031) &nbsp;12.4 Europe Forecast by Country (2026-2031) &nbsp;12.5 Middle East & Africa Forecast by Country (2026-2031) &nbsp;12.6 Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Forecast by Type (2026-2031) &nbsp;12.7 Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Forecast by Application (2026-2031) 13 Key Players Analysis &nbsp;13.1 Merck &nbsp;13.1.1 Merck Company Information &nbsp;13.1.2 Merck Dipeptide Peptidase 4 (DPP-4) Inhibitors Product Portfolios and Specifications &nbsp;13.1.3 Merck Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.1.4 Merck Main Business Overview &nbsp;13.1.5 Merck Latest Developments &nbsp;13.2 Eli Lilly &nbsp;13.2.1 Eli Lilly Company Information &nbsp;13.2.2 Eli Lilly Dipeptide Peptidase 4 (DPP-4) Inhibitors Product Portfolios and Specifications &nbsp;13.2.3 Eli Lilly Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.2.4 Eli Lilly Main Business Overview &nbsp;13.2.5 Eli Lilly Latest Developments &nbsp;13.3 AstraZenica &nbsp;13.3.1 AstraZenica Company Information &nbsp;13.3.2 AstraZenica Dipeptide Peptidase 4 (DPP-4) Inhibitors Product Portfolios and Specifications &nbsp;13.3.3 AstraZenica Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.3.4 AstraZenica Main Business Overview &nbsp;13.3.5 AstraZenica Latest Developments &nbsp;13.4 Boehringer Ingelheim &nbsp;13.4.1 Boehringer Ingelheim Company Information &nbsp;13.4.2 Boehringer Ingelheim Dipeptide Peptidase 4 (DPP-4) Inhibitors Product Portfolios and Specifications &nbsp;13.4.3 Boehringer Ingelheim Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.4.4 Boehringer Ingelheim Main Business Overview &nbsp;13.4.5 Boehringer Ingelheim Latest Developments &nbsp;13.5 Takeda Pharmaceutical Company &nbsp;13.5.1 Takeda Pharmaceutical Company Company Information &nbsp;13.5.2 Takeda Pharmaceutical Company Dipeptide Peptidase 4 (DPP-4) Inhibitors Product Portfolios and Specifications &nbsp;13.5.3 Takeda Pharmaceutical Company Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.5.4 Takeda Pharmaceutical Company Main Business Overview &nbsp;13.5.5 Takeda Pharmaceutical Company Latest Developments &nbsp;13.6 BMS &nbsp;13.6.1 BMS Company Information &nbsp;13.6.2 BMS Dipeptide Peptidase 4 (DPP-4) Inhibitors Product Portfolios and Specifications &nbsp;13.6.3 BMS Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.6.4 BMS Main Business Overview &nbsp;13.6.5 BMS Latest Developments 14 Research Findings and Conclusion

Report	Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Market Growth 2025-2031
Selected License	Multi ID: LPI24305

Buyer Information

Order Summary